Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Among authors: leleu x. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP. Santos DD, et al. Among authors: leleu x. Clin Lymphoma Myeloma. 2006 May;6(6):478-83. doi: 10.3816/CLM.2006.n.029. Clin Lymphoma Myeloma. 2006. PMID: 16796779
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H. Harousseau JL, et al. Among authors: leleu x. Haematologica. 2006 Nov;91(11):1498-505. Epub 2006 Oct 17. Haematologica. 2006. PMID: 17043025 Clinical Trial.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. Alsayed Y, et al. Among authors: leleu x. Blood. 2007 Apr 1;109(7):2708-17. doi: 10.1182/blood-2006-07-035857. Blood. 2007. PMID: 17119115 Free PMC article.
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM. Francis LK, et al. Among authors: leleu x. Clin Cancer Res. 2006 Nov 15;12(22):6826-35. doi: 10.1158/1078-0432.CCR-06-1331. Clin Cancer Res. 2006. PMID: 17121904
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM. Moreau AS, et al. Among authors: leleu x. Blood. 2007 Jun 1;109(11):4964-72. doi: 10.1182/blood-2006-10-054577. Epub 2007 Feb 6. Blood. 2007. PMID: 17284528 Free article.
Emerging drugs in multiple myeloma.
Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Ghobrial IM, et al. Among authors: leleu x. Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. doi: 10.1517/14728214.12.1.155. Expert Opin Emerg Drugs. 2007. PMID: 17355220 Review.
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Younes H, et al. Among authors: leleu x. Clin Cancer Res. 2007 Jul 1;13(13):3771-5. doi: 10.1158/1078-0432.CCR-06-2921. Clin Cancer Res. 2007. PMID: 17606706 Review.
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Ghobrial J, et al. Among authors: leleu x. Oncology (Williston Park). 2007 Jun;21(7):785-92; discussion 798-800. Oncology (Williston Park). 2007. PMID: 17722741 Free article. Review.
383 results